Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy.

[1]  C. Rödel,et al.  The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[2]  Toby C. Cornish,et al.  Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy , 2017, JAMA oncology.

[3]  P. Sharma,et al.  Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[4]  A. Hackshaw,et al.  Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial , 2017, The Lancet. Oncology.

[5]  J. Palefsky,et al.  Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Emancipator,et al.  Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  C. Rödel,et al.  Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy , 2017, Oncoimmunology.

[8]  Dae Won Kim,et al.  EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience , 2017, Oncology.

[9]  S. Kalnicki,et al.  Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Scarpi,et al.  No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) , 2016, Scientific Reports.

[11]  C. Eng,et al.  Epidermal growth factor receptor inhibition in metastatic anal cancer , 2016, Anti-cancer drugs.

[12]  S. Richon,et al.  Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection , 2016, British Journal of Cancer.

[13]  M. Guren,et al.  Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. , 2015, European journal of cancer.

[14]  C. Eng,et al.  Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. , 2015, Journal of gastrointestinal oncology.

[15]  Joe Y. Chang,et al.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. , 2015, Cancer treatment reviews.

[16]  E. Siegel,et al.  Programmed cell death-Ligand 1 (PD-L1) expression and outcome in patients with squamous cell cancer of anal canal (SCCAC). , 2015 .

[17]  J. Bouček,et al.  Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma , 2015, Oncoimmunology.

[18]  E. Scarpi,et al.  KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC) , 2014, PloS one.

[19]  J. Pignon,et al.  Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  L. Castro,et al.  Phase 1 study of cetuximab in combination with 5‐fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma , 2013, Cancer.

[21]  M. Schmid,et al.  Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer , 2012, Case Reports in Oncology.

[22]  R. Hofheinz,et al.  Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status , 2009, Oncology.

[23]  M. Zampino,et al.  K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment? , 2009, Cancer Chemotherapy and Pharmacology.

[24]  Z. Fishelson,et al.  Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development. , 2009, Molecular immunology.

[25]  S. Schwartz,et al.  Anal cancer incidence and survival: The Surveillance, Epidemiology, and End Results experience, 1973–2000 , 2004, Cancer.

[26]  M. Clark,et al.  Cancer of the anal canal. , 2004, The Lancet. Oncology.

[27]  M. Ducreux,et al.  [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. , 1999, Bulletin du cancer.

[28]  R. Pazdur,et al.  Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. , 1993, American journal of clinical oncology.

[29]  J. Ajani,et al.  Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. , 1989, The American journal of medicine.

[30]  M. Namer,et al.  Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. , 1986, Cancer treatment reports.

[31]  V. Vaitkevicius,et al.  Combined therapy for cancer of the anal canal: A preliminary report , 1974, Diseases of the colon and rectum.

[32]  A. Benson,et al.  Epidemiology of Anal Canal Cancer. , 2017, Surgical oncology clinics of North America.

[33]  M. van Egmond,et al.  Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. , 2014, Current topics in microbiology and immunology.

[34]  Patrice Ravel,et al.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. , 2013, Cancer research.

[35]  M. Brown,et al.  A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer , 2013, Journal of Hematology & Oncology.

[36]  G. Tanum.  Treatment of relapsing anal carcinoma. , 1993, Acta oncologica.